Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645476 | 0.86 | HTR1A (0.42) | ABCB1HTR1ADRD2HTR2CKMT2A | |
| SCHEMBL3499337 | 0.85 | ALOX5AP (0.37) | ABCB1HTR1AHTR2CALOX5APFEN1 | |
| SCHEMBL29396495 | 0.84 | ABCB1 (0.50) | ABCB1HTR1ADRD2HTR2CKMT2A | |
| SCHEMBL20577705 | 0.84 | ABCB1 (0.50) | ABCB1HTR1ADRD2HTR2CKMT2A | |
| SCHEMBL28153816 | 0.82 | ABCB1 (0.38) | ABCB1HTR1ASMN1; SMN2HIF1AALOX5AP | |
| SCHEMBL28555522 | 0.82 | ABCB1 (0.40) | ABCB1KMT2AMEN1NR3C1SIGMAR1 | |
| SCHEMBL851115 | 0.81 | HTR2C (0.34) | ABCB1HTR1AHTR2CS1PR1HPGD | |
| SCHEMBL27901929 | 0.80 | ABCB1 (0.46) | ABCB1HTR1ADRD2KMT2AMEN1 | |
| SCHEMBL28204910 | 0.79 | ABCB1 (0.60) | ABCB1DRD2HTR2CKMT2AMEN1 | |
| Phosphine SCHEMBL11895753 | 0.78 | ABCB1 (0.45) | ABCB1HTR1ADRD2HTR2CKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 620 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182496-A1 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | HALCYON LABS PRIVATE LIMITED (IN) | 2024-06-06 | — | — | US | claimed |
| EP-3704100-B1 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | HALCYON LABS PRIVATE LTD (IN) | 2023-08-30 | — | — | EP | claimed |
| EP-3737685-B1 | PROCESS FOR THE PREPARATION OF CRISABOROLE AND ITS INTERMEDIATES | HALCYON LABS PRIVATE LTD (IN) | 2023-03-29 | — | — | EP | claimed |
| US-11014944-B2 | Process for the preparation of crisaborole and its intermediates | HALCYON LABS PRIVATE LIMITED (IN) | 2021-05-25 | — | — | US | claimed |
| EP-3818038-A1 | PROCESS FOR THE PRODUCTION OF ARYLAMINES | Merck Patent GmbH (DE) | 2021-05-12 | — | — | EP | claimed |
| US-20210070778-A1 | NOVEL PROCESS FOR THE PREPARATION OF CRISABOROLE AND ITS INTERMEDIATES | HALCYON LABS PRIVATE LIMITED (IN) | 2021-03-11 | — | — | US | claimed |
| EP-3737685-A1 | PROCESS FOR THE PREPARATION OF CRISABOROLE AND ITS INTERMEDIATES | Halcyon Labs Private Limited (IN) | 2020-11-18 | — | — | EP | claimed |
| EP-3704100-A1 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | Halcyon Labs Private Limited (IN) | 2020-09-09 | — | — | EP | claimed |
| US-20200262848-A1 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | HALCYON LABS PRIVATE LIMITED (IN) | 2020-08-20 | — | — | US | claimed |
| WO-2020007770-A1 | PROCESS FOR THE PRODUCTION OF ARYLAMINES | MERCK PATENT GMBH (DE) | 2020-01-09 | — | — | WO | claimed |
| CN-110359097-A | The method that On-DNA aromatic compound is obtained by Suzuki coupling reaction in the building of DNA encoding compound library | 上海药明康德新药开发有限公司 | 2019-10-22 | — | — | CN | claimed |
| CN-110331447-A | The method of On-DNA aryl acetylene hydrocarbon compound is prepared in the building of DNA encoding compound library | 上海药明康德新药开发有限公司 | 2019-10-15 | — | — | CN | claimed |
| CN-109661399-A | Cross-coupling methods | 芝诺罗耶尔蒂里程碑有限责任公司 | 2019-04-19 | — | — | CN | claimed |
| US-20260040813-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12528819-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-1904494-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2008009691-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS PESTICIDES | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007046548-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006091671-A1 | IMIDAZO (1, 2-A) PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070778-A1 | NOVEL PROCESS FOR THE PREPARATION OF CRISABOROLE AND ITS INTERMEDIATES | UGT2B17, SQLE, CYP11B1 | ABCB1 131/4885HTR1A 2773/4885DRD2 4384/4885 |
| US-20260040813-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, MSRB3, GSR | ABCB1 3785/4885HTR1A 3145/4885DRD2 205/4885 |
| US-20240182496-A1 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | TALDO1, TFPI, SQLE | ABCB1 169/4885HTR1A 4558/4885DRD2 4627/4885 |
| US-12528819-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GABRA5, GRM5, GABRE | ABCB1 1073/4885HTR1A 251/4885DRD2 229/4885 |
| US-20200262848-A1 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | TALDO1, TFPI, SQLE | ABCB1 169/4885HTR1A 4558/4885DRD2 4627/4885 |
| US-11014944-B2 | Process for the preparation of crisaborole and its intermediates | UGT2B17, SQLE, UGT2B7 | ABCB1 178/4885HTR1A 3040/4885DRD2 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.